While Legend Biotech Corp ADR has underperformed by -0.12%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LEGN fell by -1.63%, with highs and lows ranging from $47.79 to $27.34, whereas the simple moving average fell by -8.06% in the last 200 days.
On October 07, 2025, Cantor Fitzgerald started tracking Legend Biotech Corp ADR (NASDAQ: LEGN) recommending Overweight. A report published by Redburn Atlantic on October 08, 2024, Initiated its previous ‘Buy’ rating for LEGN. Truist also rated LEGN shares as ‘Buy’, setting a target price of $88 on the company’s shares in an initiating report dated June 17, 2024. H.C. Wainwright Reiterated the rating as Buy on May 24, 2024, but set its price target from $86 to $73. Deutsche Bank initiated its ‘Buy’ rating for LEGN, as published in its report on May 23, 2024. Scotiabank’s report from April 17, 2024 suggests a price prediction of $65 for LEGN shares, giving the stock a ‘Sector Outperform’ rating. Cantor Fitzgerald also rated the stock as ‘Overweight’.
Analysis of Legend Biotech Corp ADR (LEGN)
Further, the quarter-over-quarter increase in sales is 37.22%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Legend Biotech Corp ADR’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -29.71% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.57, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and LEGN is recording an average volume of 1.20M. On a monthly basis, the volatility of the stock is set at 4.28%, whereas on a weekly basis, it is put at 3.48%, with a loss of -0.37% over the past seven days. Furthermore, long-term investors anticipate a median target price of $74.58, showing growth from the present price of $32.01, which can serve as yet another indication of whether LEGN is worth investing in or should be passed over.
How Do You Analyze Legend Biotech Corp ADR Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.06%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 44.94% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
